,36 However, the independent clinical prognostic significance of CDKN2A/B homozygous deletion in IDH-wildtype glioblastoma may be important only in tumors with unmethylated MGMT promoters, where overall survival (OS) is slightly lower compared to tumors without CDKN2A/B homozygous deletion, but this difference is statistically significant (median OS of 14.7 months and 16.9 months), which is not observed in MGMT methylated tumors.37 Here, IDH1 is linked to glioblastoma.